Table 1.

Percentage of the clinical population excluded by condition studied

	Number of trials	Median percentage excluded (range excluded)a
All conditions	305	77.1 (0.0 to 100.0)
Cardiovascular conditions	81	74.7 (1.6 to 98.8)
Heart failure	25	65.0 (18.8 to 92.0)
Hypertension	22	83.0 (1.6 to 98.8)
Stroke/transient ischemic attack	21	83.6 (33.2 to 98.4)
Atrial fibrillation	4	34.9 (32.3 to 41.2)
Coronary heart disease	4	53.1 (2.8 to 84.5)
Lipid lowering for primary prevention	4	85.9 (69.7 to 89.1)
Secondary prevention of myocardial infarction	1	76.8
Diabetes mellitus	16	88.1 (29.8 to 99.0)
Type 2 diabetes	7	81.7 (49.3 to 96.5)
Diabetic ulcers	7	93.3 (29.8 to 99.0)
Type 1 diabetes	2	91.6 (87.5 to 95.6)
Respiratory conditions	78	89.4 (42.4 to 100.0)
COPD	51	84.3 (42.4 to 100.0)
Asthma	17	96.0 (64.0 to 100.0)
Bronchiectasis	10	80.1 (49.0 to 93.0)
Cancer	24	56.6 (13.6 to 81.2)
Breast cancer	12	56.6 (28.9 to 81.2)
Lung cancer	3	71.4 (65.4 to 71.9)
Renal cancer	3	13.6 (13.6 to 48.5)
Colorectal cancer	2	66.7 (65.7 to 67.6)
Bladder cancer	1	45.3
Stomach cancer	1	41.3
Lymphoma	1	70.4
Prostate cancer	1	57.1
Rheumatoid arthritis	51	84.0 (56.0 to 98.7)
HIV infection	32	42.0 (0.0 to 67.6)
Other conditions	23	58.3 (23.7 to 88.9)
Venous thromboembolism prophylaxis	9	41.5 (23.7 to 78.8)
Venous ulcers	7	83.6 (58.3 to 88.9)
Brain injury	2	40.5 (35.9 to 45.0)
Pressure ulcers	1	34.7
Alzheimer’s disease	1	86.5
Fibromyalgia	1	52.1
Irritable bowel syndrome	1	73.1
Incisional hernia	1	62.5

Abbreviations: COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus

^a Where there is only one trial–clinical population comparison, the number reported is the value for that comparison; where there are two, the median reported is the midpoint value between the two